Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China

References

• World Health Organization. Global Tuberculosis Report. World Health Organization; 2022.
   Google Scholar
• Patel RV, Riyaz SD, Park SW. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis. Curr Top Med Chem. 2014;14(16):1866–1874. doi:10.2174/1568026614666140929114822
   PubMed Web of Science ®Google Scholar
• Ismail N, Omar SV, Ismail NA, Peters RPH. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief. 2018;20:1975–1983. doi:10.1016/j.dib.2018.09.057
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466. doi:10.1371/journal.pmed.0030466
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report. World Health Organization; 2014.
   Google Scholar
• Gopal M, Padayatchi N, Metcalfe JZ, O’Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013;17(8):1001–1007. doi:10.5588/ijtld.12.0144
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report. World Health Organization; 2016.
   Google Scholar
• Villar M, Sotgiu G, D’Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2011;38(3):730–733. doi:10.1183/09031936.00195210
   PubMed Web of Science ®Google Scholar
• Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67(6):1503–1507. doi:10.1093/jac/dks078
   PubMed Web of Science ®Google Scholar
• Bloemberg GV, Keller PM, Stucki D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med. 2015;373(20):1986–1988. doi:10.1056/NEJMc1505196
   PubMed Web of Science ®Google Scholar
• Polsfuss S, Hofmann-Thiel S, Merker M, et al. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin Infect Dis. 2019;69(7):1229–1231. doi:10.1093/cid/ciz074
   PubMed Web of Science ®Google Scholar
• Pang Y, Zong Z, Huo F, et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017;61(10). doi:10.1128/AAC.00900-17
   Web of Science ®Google Scholar
• Yang JS, Kim KJ, Choi H, Lee SH. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med. 2018;38(6):563–568. doi:10.3343/alm.2018.38.6.563
   PubMed Web of Science ®Google Scholar
• Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10(2):165. doi:10.3390/pathogens10020165
   PubMed Web of Science ®Google Scholar
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271–3276. doi:10.1128/AAC.06126-11
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732. doi:10.1056/NEJMoa1313865
   PubMed Web of Science ®Google Scholar
• Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J. 2017;49(3):1601719. doi:10.1183/13993003.01719-2016
   PubMed Web of Science ®Google Scholar
• Wang G, Jiang G, Jing W, et al. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: a subsequent study of a national survey. J Infect. 2021;82(3):371–377. doi:10.1016/j.jinf.2021.02.004
   PubMed Web of Science ®Google Scholar
• He W, Liu C, Liu D, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. J Glob Antimicrob Resist. 2021;26:241–248. doi:10.1016/j.jgar.2021.06.007
   PubMed Web of Science ®Google Scholar
• Liu Y, Gao M, Du J, et al. reduced susceptibility of mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis. 2021;73(9):e3391–e3397. doi:10.1093/cid/ciaa1002
   PubMed Web of Science ®Google Scholar
• Hoffmann H, Kohl TA, Hofmann-Thiel S, et al. Delamanid and bedaquiline resistance in mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am J Respir Crit Care Med. 2016;193(3):337–340. doi:10.1164/rccm.201502-0372LE
   PubMed Web of Science ®Google Scholar
• Zheng H, He W, Jiao W, et al. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. BMC Infect Dis. 2021;21(1):330. doi:10.1186/s12879-021-06024-8
   PubMed Web of Science ®Google Scholar
• Kardan-Yamchi J, Kazemian H, Battaglia S, et al. Whole genome sequencing results associated with minimum inhibitory concentrations of 14 anti-tuberculosis drugs among rifampicin-resistant isolates of mycobacterium tuberculosis from Iran. J Clin Med. 2020;9(2):465. doi:10.3390/jcm9020465
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li T, Qu G, Pang Y, Zhao Y. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2015;45(1):71–75. doi:10.1016/j.ijantimicag.2014.09.012
   PubMed Web of Science ®Google Scholar
• Azimi T, Khoshnood S, Asadi A, et al. Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: a systematic review and meta-analysis. Front Pharmacol. 2022;13:955050. doi:10.3389/fphar.2022.955050
   PubMed Web of Science ®Google Scholar
• Habibnia S, Karami-Zarandi M, Zaker S, et al. Molecular characterization of resistance to second-line anti-mycobacterial drugs among clinical isolates of multidrug-resistant mycobacterium tuberculosis. Clin Lab. 2023;69(1). doi:10.7754/Clin.Lab.2022.220211
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Pillay M, Pillay M, et al. Primary capreomycin resistance is common and associated with early mortality in patients with extensively drug-resistant tuberculosis in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2015;69(5):536–543. doi:10.1097/QAI.0000000000000650
   PubMed Web of Science ®Google Scholar
• Shah NS, Richardson J, Moodley P, et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2011;17(3):510–513. doi:10.3201/eid1703.101363
   PubMed Web of Science ®Google Scholar
• Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31(6):1155–1159. doi:10.1183/09031936.00028708
   PubMed Web of Science ®Google Scholar